EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer

Iera Hernandez-Unzueta, Aitor Benedicto, Uxue Telleria, Eduardo Sanz, Joana Márquez iD

Nutrients · 2023

DOI: 10.3390/nu15112536 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2023. Verfasst von Iera Hernandez-Unzueta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology and Histology Department, Medicine and Nursing Faculty, University of the Basque Country, 48940 Leioa, Spain. Hauptthemen laut MEDLINE: Antineoplastic Agents, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Catalysis S.L..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate cancer is one of the most common cancers among men. Although many patients respond favorably to first-line treatments, castration—and chemotherapy—resistance arises after a few years, leading to metastasis. Thus, new approaches are being investigated using natural supplements to reinforce current therapies. Ocoxin is a plant-based mixture with antitumor properties that have been proved in several cancers. Here, we evaluated the cytotoxic capacity of this compound itself and combined with Docetaxel, Enzalutamide and Olaparib as an adjuvant agent. We observed that Ocoxin reduced tumor cell viability; slowed down cell cycles; altered the expression of genes involved in DNA replication, cell cycles and the p53 signaling pathway; and reduced migratory capacity after stimulation with cancer-associated fibroblasts (CAFs) and osteoblasts in vitro and reduced tumor volume in vivo. The combination of the nutritional supplement with chemotherapy showed a higher cytotoxic effect than chemotherapy alone and reverted chemoresistance conferred by CAFs and osteoblasts. Moreover, the adjuvant therapy also improved the outcome in vivo compared to the treatment with solo chemotherapy, where mice developed smaller tumors and less angiogenesis. Therefore, Ocoxin arises as a good candidate for further studies in combination with current treatments for prostate-cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsProstatic NeoplasmsHumansMaleAnimalsMiceTaxoidsDocetaxelAdjuvants, ImmunologicCell Line, TumorAscorbic AcidFolic AcidPantothenic AcidPlant ExtractsVitamin B 12Zinc SulfateVitamin B 6

Stichwörter der Autor:innen

adjuvantcancer nutritionchemotherapyfibroblastosteoblastprostate cancerresistancetumor microenvironment

Substanzen

TaxoidsAntineoplastic AgentsDocetaxelAdjuvants, ImmunologicOcoxinAscorbic AcidFolic AcidPantothenic AcidPlant ExtractsVitamin B 12

Autor:innen und Institutionen

  • Cell Biology and Histology Department, Medicine and Nursing Faculty, University of the Basque Country, 48940 Leioa, Spain.
  • Research and Development, Catalysis S.L., 28016 Madrid, Spain.

ORCID-Profile: Joana Márquez

Förderung

  • Catalysis S.L.

Zitieren

APA

Hernandez-Unzueta, I., Benedicto, A., Telleria, U., Sanz, E., & Márquez, J. (2023). Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer. Nutrients. https://doi.org/10.3390/nu15112536

Vancouver

Hernandez-Unzueta I, Benedicto A, Telleria U, Sanz E, Márquez J. Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer. Nutrients. 2023. doi:10.3390/nu15112536

BibTeX
@article{HernandezUnzueta2023,
  author = {Hernandez-Unzueta, Iera and Benedicto, Aitor and Telleria, Uxue and Sanz, Eduardo and Márquez, Joana},
  title = {Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15112536}
}
Kostenlos starten →